Drugs / IC14
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07481474 | Jan → Jun 2027 expected | osteoarthritis, knee | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03487263 | Oct 2017 → Apr 2018 | amyotrophic lateral sclerosis | Implicit Bioscience | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06678074 | Feb 2025 → Jun 2026 overdue | ST-elevation myocardial infarction | Implicit Bioscience | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06556810 | Oct 2024 → Apr 2026 overdue | heart failure | Implicit Bioscience | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06275893 | Mar 2024 → Aug 2025 | arrhythmogenic right ventricular dysplasia 1, familial isolated arrhythmogenic ventricular dysplasia, left dominant form | Implicit Bioscience | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT06513949 | Aug 2025 → Sep 2027 expected | acute lung injury, adult acute respiratory distress syndrome | Implicit Bioscience | Recruiting | No outcome recorded |
| Phase 2 | NCT04391309 | Apr 2021 → Feb 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT04488081 | Jul 2020 → Jul 2028 expected | COVID-19 | QuantumLeap Healthcare Collaborative | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03474263 | Sep 2019 → Apr 2021 | amyotrophic lateral sclerosis | Implicit Bioscience | Withdrawn | No outcome recorded |
| Phase 2 | NCT03017547 | Jun 2019 → Jun 2020 | acute respiratory distress syndrome | Implicit Bioscience | Withdrawn | No outcome recorded |
| Phase 2 | NCT03875560 | May 2019 → Jan 2020 | dengue disease | Implicit Bioscience | Withdrawn | No outcome recorded |
| Phase 2 | NCT00233207 | Sep 2005 → Jun 2007 | adult acute respiratory distress syndrome | University of Washington | Terminated | No outcome recorded |
| Phase 2 | NCT00042588 | May 2002 → ? | infectious disease with sepsis, pneumonia | ICOS Corporation | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT04346277 | — | COVID-19, acute respiratory distress syndrome | Implicit Bioscience | No longer available | No outcome recorded |
| — | NCT04309604 | — | amyotrophic lateral sclerosis | Implicit Bioscience | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03508453 Comparator | Aug 2021 → May 2023 | amyotrophic lateral sclerosis | Implicit Bioscience | Withdrawn | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IC14 | “The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.” NCT00042588 ↗12“Atibuclimab (IC14) is a monoclonal antibody against human cluster of differentiation (CD)14, a key signaling molecule of the innate immune system” NCT06556810 ↗ “Atibuclimab (IC14), 20 mg/kg intravenously, once” NCT06678074 ↗ |
| Known as | anti-CD14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04391309 ↗ |
| Known as | atibuclimab | “The primary objective was to demonstrate the safety and tolerability of monoclonal antibody against CD14 (IC14) (atibuclimab) in amyotrophic lateral sclerosis patients.” PMID 34678870 ↗ Oct 20215“IC14 (atibuclimab) is a monoclonal anti-CD14 antibody.” PMID 36533976 ↗ Dec 2022 |
| Action | Inhibit | “to block CD14 medicated cellular activation” NCT00233207 ↗ |
| Modality | Monoclonal antibody | “Recombinant Chimeric Monoclonal Antibody” NCT00042588 ↗ |
| Route | Intravenous | “IC14 4 mg/kg IV on Study Day 1” NCT03017547 ↗ |
| Target | CD14 | “a recombinant chimeric monoclonal antibody (mAb) recognizing CD14” NCT00233207 ↗ |